therapeutic action: antidepressant effects

Are Side Effects Necessary for Antidepressive Treatment: The Psilocybin Experience

Researchers are studying psilocybin (a compound from certain mushrooms) as a potential treatment for depression. However, there is debate about whether the hallucinogenic side effects are necessary for its therapeutic benefits. This paper argues that new research suggests the antidepressant effects work through specific brain pathways (serotonin, opioid, and glutamate systems) that don’t require hallucinations. The author suggests developing safer, non-hallucinogenic antidepressants that maintain the same therapeutic benefits.

Read More »

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

This review examines the safety of psilocybin therapy for treating anorexia nervosa, a serious eating disorder with limited treatment options. The authors analyze how psilocybin’s common side effects (like increased heart rate, nausea, and dizziness) interact with medical complications already present in people with anorexia. Based on early clinical trials, they conclude that psilocybin can be safely used in this population with proper medical screening and monitoring protocols tailored to their specific vulnerabilities.

Read More »

A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe

Scientists have discovered that magic mushrooms contain compounds called psilocybin and psilocin that show promise in treating depression and other psychiatric conditions. However, extracting enough of these compounds from mushrooms is difficult, so chemists have developed multiple ways to synthesize them in laboratories. This review examines different chemical and biological methods for producing these therapeutic compounds, from traditional synthesis techniques to modern approaches using special catalysts and enzymes, making these medicines more accessible for clinical research.

Read More »

Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond

Researchers created new chemical versions of psilocybin (the active compound in magic mushrooms) that cannot be broken down by the body’s natural enzymes in the same way. They tested these new compounds to see if they could help with depression and anxiety by targeting specific brain receptors. The best compound worked well on the intended brain receptors but importantly showed less activity on a heart-related receptor, potentially making it safer than natural psilocybin.

Read More »

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults – A Systematic Review

Psilocybin, a naturally occurring compound found in certain mushroom species, shows significant promise as a treatment for depression. Clinical studies reviewed in this research found that psilocybin-assisted therapy reduced depressive symptoms in every patient studied, with improvements lasting months after treatment. Unlike traditional antidepressants, psilocybin caused only mild temporary side effects and worked faster, suggesting it could become an important alternative treatment for depression.

Read More »

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

This review examines how psilocybin may help treat depression by increasing empathy and prosocial behavior. While psilocybin leaves the body within hours, its antidepressant effects can last months, and researchers believe empathy and helping others may explain this lasting benefit. The authors suggest psilocybin starts a positive cycle where increased empathy leads to helping others, which boosts mood and well-being, which further reinforces empathetic behavior.

Read More »

Study protocol for ‘Psilocybin in patients with fibromyalgia: brain biomarkers of action’

Researchers are testing whether psilocybin (the active compound in magic mushrooms) combined with therapeutic support can help people with fibromyalgia, a chronic pain condition. The study will measure brain activity using EEG and brain imaging to understand how psilocybin might reduce pain and improve mental health. Twenty patients will receive guided psilocybin sessions over eight weeks while researchers track changes in brain function and pain levels.

Read More »

The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses

Researchers used computer-based analysis to understand how psilocybin, a compound found in certain mushrooms, might help prevent suicide. They identified four key proteins that psilocybin interacts with and found that it works through serotonin and calcium signaling pathways in the brain, which are known to be involved in depression and suicidal behavior. While these findings are promising, more research is needed to confirm these effects in humans before psilocybin can be used clinically for suicide prevention.

Read More »

Psychedelic-assisted therapy – supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics

This paper critically examines recent clinical trials testing MDMA and psilocybin for treating PTSD and depression. While these trials reported promising results, the author identifies serious scientific and ethical problems: participants could tell whether they received the drug or placebo due to its strong effects, researchers and therapists who strongly believed in the treatment may have unconsciously influenced patient responses, and negative side effects may have been downplayed. The author argues that without fixing these problems, the entire field of psychedelic therapy research could lose credibility.

Read More »

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models

This paper addresses confusion about how ketamine and psychedelics are being used to treat mental health conditions like depression and PTSD. The authors propose new clear definitions to distinguish whether these drugs are used alone for their chemical effects, combined with established talk therapies, or used to create experiences that are then processed in therapy. Using these clearer definitions will help patients, doctors, and regulators better understand what treatments involve and make more informed decisions.

Read More »
Scroll to Top